Biotechnology News

PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal...

SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and...

Merakris advances a potentially pivotal MTX-001 Phase 2/3 strategy following FDA feedback as it prepares its first commercial-pilot GMP drug lot.

Company announcement no. 43 - 2627 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

PS-003 is designed to address the underlying genetic cause of X-linked Alport Syndrome (XLAS), and new preclinical data demonstrate the restoration of COL4A5, the key collagen protein absent or...

Company announcement no. 42 - 2627 October 2026 Notification of holding of treasury shares Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that as of 26 October...

2026 operating profit expected to reach CHF 115 million (previously CHF 70 million) driven by higher than expected Cresemba and Zevtera-related revenue of CHF 250 million (previously CHF 210...

Erwarteter Anstieg des Betriebsgewinns 2026 auf CHF 115 Mio. (zuvor CHF 70 Mio.), getragen von höher als erwarteten Cresemba- und Zevtera-basierten Umsätzen in Höhe von CHF 250 Mio. (zuvor CHF 210...

Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform

Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable...